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doi:10.1016/j.kjms.2012.04.017Abstract Dermatofibroma (DF) and dermatofibrosarcoma protuberans (DFSP) are the spindle
cell mesenchymal neoplasms of the dermis and subcutis. Their histogenesis still remains uncer-
tain and controversial. Traditionally, CD34 and factor XIIIa or other markers have been widely
used to distinguish these two diseases. However, the results of these markers reveal overlap-
ping and they lack specificity. Formalin-fixed, paraffin-embedded blocks were collected from
the biopsied cases in Kaohsiung Medical University Hospital in Taiwan between 2004 and 2006.
This study included 19 cases of DF and 17 cases of DFSP. Immunohistochemical analysis using
antibodies CD34, matrix metalloproteinases (MMP)-2, MMP-9, and MMP-11 was performed.
We found that the expression of CD34, MMP-2 and MMP-11 shows significant statistical differ-
ences in Immunohistochemistry (IHC) study positive or negative reactivity (positive of CD34 in
DFSP and positive of MMP-2 and MMP-11 in DF; pZ 0.03, p< 0.001, and p< 0.001, respectively)
between DF and DFSP. The result for expression of MMP-9 reveals no differences. The results
indicate that the pathogenesis of DF and DFSP are affected by different expressions of extra-
cellular matrix proteins. Metalloproteinases may play a direct role in these two diseases. Since
no single marker can completely distinguish DF from DFSP, a combination of more than two or
three stains may elevate the accuracy of diagnosis.
Copyright ª 2012, Elsevier Taiwan LLC. All rights reserved.of Pathology, Kaohsiung Medical University Hospital, Number 100, Tzyou 1st Road, Kaohsiung 807,
w (C.-Y. Chai).
vier Taiwan LLC. All rights reserved.
Table 1 MMP-2, MMP-9, MMP-11 and CD 34 Immunoreac-
tivity in DF and DFSP.
DF (nZ 19) DFSP (nZ 17) p value*
CD34
Positive 4 12 0.03
Negative 15 5
MMP-2
Positive 19 3 < 0.001
Negative 0 14
MMP-9
Positive 19 17 1.0
Negative 0 0
MMP-11
Positive 17 5 < 0.001
Negative 2 12
*p value was determined by Chi-square test.
DFZ dermatofibroma; DFSPZ dermatofibrosarcoma protuber-
ans; MMZmatrix metalloproteinases.
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Dermatofibroma (DF) and dermatofibrosarcoma protuberans
(DFSP) are both mesenchymal neoplasms of spindle-shaped
cell tumors in the dermis and subcutis. Histologically, DFSP
tends to diffusely infiltrate the dermis and invade into
subcutaneous tissue, along the fibrous septa of fat, resulting
in a honeycomb appearance. DF is predominantly a dermal
lesion but may involve the upper part of the dermis some-
times. DF variant as cellular fibrous histiocytoma sometimes
involves subcutaneous fat. Therefore, in clinical practice, it
challenges pathologists to make a diagnosis according to
routine hematoxylin and eosin (H&E) staining in some gray-
zone cases. In addition, histogenesis remains uncertain and
controversial until now. For prognosis, DFSP has a signifi-
cantly higher risk of local recurrence [1] than DF and can
metastasize especially in the case of the fibrosarcomatous
variant [2]. Therefore, it is important to make a correct
diagnosis for prognosis prediction and treatment strategy.
Traditionally, CD34 and factor XIIIa have been widely
used to distinguish these two diseases [3e5]. Other
immunohistochemical (IHC) markers such as COX-2 [6],
CD117 [7], Nestin [8], Apo D [9], and High mobility group A
(HMG-A) [10] have also been studied. However, the results
of these markers leave an overlap and a lack of the
specificity. In a previous study, the matrix metal-
loproteinases (MMPs) family is known to be capable of
regulation of connective tissue turnover by cell-matrix
interactions [11]. It also has been suggested that
increased proteolysis is a potential mechanism for cancer
cells to penetrate the basement membrane, enter the
interstitial stroma and metastasize to distant sites [12]. In
our study, we evaluate the expression of MMP-2, MMP-9,
and MMP-11, which are synthesized by dermal fibroblasts in
DF and DFSP, and in an attempt to differentiate and
understand the pathogenesis of these two neoplasms.
Materials and methods
Formalin-fixed, paraffin-embedded blocks of dermatofi-
broma and dermatofibrosarcoma protuberans were
collected from biopsies in Kaohsiung Medical University
Hospital between 2004 and 2006. The H&E slides were
reviewed to confirm the diagnosis. This study included 19
cases of DF and 17 cases of DFSP. We chose only extremely
confirmed cases of DF and DFSP, diagnoses of which were
made according to the criteria published in Health Orga-
nization Classification of Skin Tumors [13]. The study was
approved by the Institutional Review Board of Kaohsiung
Medical University Hospital (KMUH-IRB-980340).
IHC stainingwas performed using theMMP-2, MMP-9, MMP-
11 (1:75, NeoMarkers, Union City, CA, USA) and CD34 (1:50,
DAKO, Glostrup, Denmark) antibody. Then, a Ventana (Tuc-
son, AZ, USA) automated instrumentwas used for IHC staining
according to the manufacturer’s guidelines. Finally, the
tissue sections were counterstained by Mayer hematoxylin
and dehydrated in increasing grades of alcohols cleared in
xylene and mounted. Negative controls were obtained by
replacing the primary antibody with nonimmune serum.
IHC studies were evaluated semiquantitatively according
to the method of a previously published paper [14]. Scoringwas semiquantitative based on the number of spindled
tumor cells stained in the whole tumor. Positive reactivity
was defined as cytoplasmic and was graded in the following
manner: 0, no reactivity; þ1, 1e10% of tumor cells reac-
tive; þ2, 11e25% of tumor cells reactive; þ3, 26e50% of
cells reactive; þ4, 51e75% % of cells reactive; and þ5, with
> 75% of cells reactive. For further analysis, using a cut-off
point to define two groups of negative and positive staining,
e, 1þ staining patterns were regarded as negative, and
2þ w 5þ staining patterns were regarded as positive. Two
pathologists blinded to the clinical outcome independently
evaluated the immunostaining patterns. If a discrepancy
was present, the pathologists re-analyzed the slides
together and reached a consensus regarding the final score.
For statistical analysis, the correlations of CD34, MMP-2,
MMP-9, and MMP-11 expression were assessed using the
Chi-square test. All statistical analyses were performed
with the SPSS 15.0 statistical software program (Chicago,
IL, USA). The p values less than 0.05 were considered to be
statistically significant.
Results
The results of immunoreactivities for CD34, MMP-2, MMP-9
and MMP-11 in DF and DFSP are summarized in Table 1.
Immunoreactivity for CD34
Several endothelial cells and spindle cells in the reticular
dermis in both DF and DFSP were demonstrated by CD34
staining as positive internal control. In most cases of DF,
CD34 was completely negative (15 of 19, 80%). This is shown
in Fig. 1. Of the other four DF cases, two cases showed
a weakly positive (Score 2) staining and two cases disclosed
a strong positive (Score 5) staining. On the other hand,
CD34 expression was noted as strong positive level (Score 5)
in 12 of the 17 DFSPs and five cases were negative. The
CD34 IHC reactivity was significantly more positive in DFSP
compared with that in DF (pZ 0.03).
Figure 1. Immunohistochemical expression of DF; and DFSP stained with antibody to CD34, MMP-2, and MMP-11. Original
magnification 200. (A) Only endothelial cells among the tumor cells show immunoreactivity to CD34 in DF; (B) the tumor cells
show strong immunoreactivity to CD34 in DFSP; (C) the tumor cells show intense immunoreactivity to MMP-2 in DF; (D) the tumor
cells show no immunoreactivity to MMP-2 in DFSP; (E) the tumor cells show intense immunoreactivity to MMP-11 in DF; (F) the tumor
cells show no immunoreactivity to MMP-11 in DFSP. DFZ dermatofibroma; DFSPZ dermatofibrosarcoma protuberans;
MMPZmatrix metalloproteinases.
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In IHC expression of MMP-2 stain, 19 cases (100%) of DF
showed positive cytoplasmic staining (> 10% tumor cells).
The results are shown in Fig. 1. Seven cases showed
moderate staining (Score 2e3) and 12 cases were strong
positive (Score 4e5). By contrast, only three cases (17.6%)
of DFSP showed weak expression (Score 2e3) of MMP-2. The
other 14 cases were negative for MMP-2 stain (9 Score 0 and
5 Score 1). The MMP-2 IHC reactivity was significantly more
positive in DF compared with that in DFSP (p< 0.001).
Immunoreactivity for MMP-9
IHC expression of MMP-9 stain, 19 cases (100%) of DF
showed strong positive (19 cases score 5) and 17 cases of
DFSP showed moderate-to-strong positive (3 cases score 4and 14 cases score 5). There was no statistical significance
between these two neoplasms in MMP-9 staining.
Immunoreactivity for MMP-11
Immunoreactivity for MMP-11 was expressed in the cyto-
plasm of the spindle cells in DFs. At low-power view, tumor
cells were positively stained and contrasted strongly with
the surrounding adjacent dermis or subcutaneous fat.
Eccrine ducts were also stained as a positive internal
control [14]. In DF, ST3 was positive (Score 2e5) in most
cases (17/19, 89%). Only two cases shows negative for MMP-
11 stain (Score 1). By contrast, in 12 of 17 DFSPs, the tumor
cells were negative for MMP-11 (71%). Five cases of DFSP
showed moderate to strong positive (Score 3e5) MMP-11
staining. The MMP-11 IHC reactivity was significantly more
positive in DF than in DFSP (p< 0.001).
Table 2 Previous Studies of MMP-2, MMP-9, and MMP-11 in DF and DFSP.
Reference DF: positive/total case (%) DFSP: positive/total case (%)
MMP-2 MMP-9 MMP-11 MMP-2 MMP-9 MMP-11
Weinrach DM et al. [1] 21/45 (47%) 9/45 (20%) 0/41(0%) 0/36 (%) d
Unden et al. [26] d d 19/19 (100%) d d 0/7 (0%)
Thewes et al. [27] d d 23/40 (57.5%) d d 1/8 (12.5%)
Cribier et al. [14] d d 40/40 (100%) d d 0/40 (0%)
H. J. Kim [13] d d 23/23 (100%) d d 1/17 (5.9%)
DFZ dermatofibroma; DFSPZ dermatofibrosarcoma protuberans; MMZmatrix metalloproteinases.
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DF and DFSP are the both spindle-shaped cell mesenchymal
neoplasms of the dermis and subcutis. Statistically, DFSP
has higher risk of recurrence than DF [1] and it can
metastasize especially in the case of the fibrosarcomatous
variant [2]. However, their pathogenesis remains still
unclear. Histologically, DFSP is difficult to differentiate
from DF variants due to sometime identical characteristics.
Therefore, making the correct diagnosis according to H&E
staining is still a challenge for dermatopathologists in some
cases.
In previous studies, numerous IHC markers were been
used to distinguish DF from DFSP. Traditionally, CD34 and
factor XIIIa were most widely used as the tools to differ-
entiate these two diseases [3e5]. Other IHC markers, such
as COX-2 [6], CD117 [7], Nestin [8], Apo D [9], CD44, hya-
luronate [15] , D2-40 [16], CD163 [17], and HMG-A [10],
have also been studied. Ultrastructural study [18] or gene
analysis [19e21] have also been performed. However, these
markers or techniques leave an overlap and they lack
specificity.
The MMPs family is known to be capable of regulation of
connective tissue turnover by cell-matrix interactions [11].
MMPs play a key role in cancer progression. For example,
MMP-1, MMP-2, and MMP-9 are involved in the initial
breakdown of collagen and basement membrane compo-
nents during tumor growth and invasion [22]. The expres-
sion of MMP-2 and MMP-9 was found to correlate with
ras-mediated cellular transformation and to be a function
of malignant potential [23]. Nevertheless, to date, few
studies have investigated the expression of MMP-2, MMP-9,
and MMP-11 in DF and DFSP [1,24e27]. The possible path-
ogenesis of these two diseases is still controversial.
Therefore, we chose gelatinase A/type IV collagenase
(MMP-2, 72kb), gelatinase B/type IV collagenase (MMP-9,
92kb) and stromelysin-3 (MMP-11) as the IHC markers based
on the following evidence. First, DF and DFSP are composed
of predominant spindle-shaped cell resembling fibroblasts.
We wished to demonstrate the interactions of MMPs and
fibroblasts. Second, MMP-11 was found to be a useful
marker for the differential diagnosis of DF and DFSP,
whereas DFSPs were rarely positive for MMP-11 stain
[24,27,28]. We wished to compare different IHC markers to
distinguish DF from DFSP (Table 2) [1,13,14,26,27].
In our study, we found significant IHC expression (> 10%
tumor cells) of CD34 in DFSP, MMP-2 (100%) and MMP-11 (89%)
in DF. The mean standard deviation (SD) IHC score ofCD34, MMP-2, and MMP-11 shows significant statistical
differences (0.03, < 0.001, and < 0.001, respectively)
between DF and DFSP. The expression of CD34, MMP-2, and
MMP-11 is similar to the previous studies in DF and DFSP
[1,3e5,14,24,25,27e29]. Although a higher expression of
MMP-2 was found in a lot of cancers, it seemed that MMP-2
was not regulated only just at the transcriptional level,
but also that it was governed by other enzyme activators and
inhibitors [1]. Several factors may mediate and influence
MMP-2 expression. Since zymography is a certain way to
evaluate the functions of MMPs, further study of MMP-2
function in cells is needed.
Alternatively, the result of expression of MMP-9 in our
study is quite different from the Weinrach study [1]. Nine of
45 cases in DF and none in DFSP in their study are positive
for MMP-9. All of our cases, both DF and DFSP, are strongly
positive for MMP-9 staining. These discrepancies may be
attributed to several factors, such as case numbers,
immunohistochemical techniques, scoring methods, and
even antigen retrieval.
Our study suggests that the pathogenesis of DF and DFSP
are affected by different interactions of extracellular
matrix proteins. MMPs may play a direct role in the
progression of these two diseases. Further research is
therefore necessary to determine the mechanisms in more
detail. For some cases in which a definite diagnosis by H&E
staining is difficult, IHC study can provide an assistant role.
As no single marker can distinguish DF from DFSP
completely, a combination of more than two or three
stainings (data not shown) may elevate the accuracy of
diagnosis.
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